Loading...
XNASOPTN
Market cap56mUSD
Jan 08, Last price  
5.66USD
1D
-5.03%
1Q
770.77%
IPO
-71.14%
Name

OptiNose Inc

Chart & Performance

D1W1MN
XNAS:OPTN chart
P/E
—
P/S
0.80
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.03%
Rev. gr., 5y
58.64%
Revenues
71m
-6.93%
85,00047,500,00007,065,00034,631,00049,117,00074,652,00076,276,00070,987,000
Net income
-35m
L-53.55%
-28,314,00022,613,000-48,902,000-106,658,000-108,945,000-98,330,000-81,650,000-76,395,000-35,483,000
CFO
-21m
L-69.65%
-28,714,00021,720,000-35,651,000-91,817,000-90,815,000-86,206,000-76,935,000-67,651,000-20,532,000
Earnings
Mar 05, 2025

Profile

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
URL
https://www.optinose.com/
IPO date
Oct 13, 2017
Employees
141
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
70,987
-6.93%
76,276
2.18%
Cost of revenue
13,936
24,523
Unusual Expense (Income)
NOPBT
57,051
51,753
NOPBT Margin
80.37%
67.85%
Operating Taxes
1,562
Tax Rate
3.02%
NOPAT
57,051
50,191
Net income
(35,483)
-53.55%
(76,395)
-6.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
599
52,288
BB yield
-0.41%
-32.90%
Debt
Debt current
131,138
130,546
Long-term debt
2,133
3,221
Deferred revenue
Other long-term liabilities
17,200
21,491
Net debt
59,587
39,523
Cash flow
Cash from operating activities
(20,532)
(67,651)
CAPEX
(328)
(63)
Cash from investing activities
(328)
(63)
Cash from financing activities
300
51,436
FCF
55,559
50,743
Balance
Cash
73,684
94,244
Long term investments
Excess cash
70,135
90,430
Stockholders' equity
(720,348)
(684,866)
Invested Capital
782,691
780,905
ROIC
7.30%
6.69%
ROCE
91.51%
53.89%
EV
Common stock shares outstanding
112,080
85,900
Price
1.29
-30.27%
1.85
14.20%
Market cap
144,583
-9.02%
158,915
72.55%
EV
204,170
198,438
EBITDA
57,453
52,285
EV/EBITDA
3.55
3.80
Interest
19,528
16,843
Interest/NOPBT
34.23%
32.54%